Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCHOTT to Strengthen Pharmaceutical Site in Hungary

Published: Monday, June 10, 2013
Last Updated: Sunday, June 09, 2013
Bookmark and Share
New maintenance facility will be opened in the Lukácsháza region.

SCHOTT Pharmaceutical Systems has announced plans to significantly expand its Hungarian site Lukácsháza that manufactures pharmaceutical primary packaging.

Investments in the mid-double-digit million euro range are planned from now until 2016.

The first step will be to open a new maintenance facility for overhauling and upgrading production machines that will create more than 30 new jobs in the Lukácsháza region.

In addition, production capacity should continue to increase in Hungary over the next few years.

SCHOTT manufactures ampoules, vials, and cartridges or so-called primary packaging for the pharmaceutical industry at its site in Lukácsháza near the Hungarian-Austrian border. The plant has continued to grow since it first opened in 1993.

Today, Lukácsháza, with its roughly 530 employees and annual production of more than 1.7 billion units, is the SCHOTT Pharmaceutical Division's single largest site.

The products manufactured in Lukácsháza are mainly exported to all parts of Europe and overseas, but also produced for the local market.

In addition to opening this global maintenance center, SCHOTT has also established a team of experts at this site that will overhaul its production machines on a regular basis and upgrade them to meet the latest technical standards.

“By doing so, we actively demonstrate our commitment to living up to the highest standards for quality and maintaining these over the long-term, in fact even for all of our global plants,” explains Dr. Jürgen Sackhoff, Vice President of SCHOTT Pharmaceutical Systems.

For Dr. Frank Heinricht, Chairman of the Board of Management, the expansion of the site in Hungary is only part of what can be considered a global investment strategy. After all, SCHOTT also intends to install new production lines in Hungary over time.

“On average, our annual production of ampoules, cartridges and vials will increase by almost half at this site,” Heinricht says and adds, “With our investment strategy, we will be helping our customers around the world to meet their quality and growth targets.”

The company also opened a new plant in India just recently and significantly expanded its capacities in Indonesia and Russia. A new joint venture in China also further expands its global manufacturing network.

Strong base in the region

SCHOTT’s expansion in Hungary also sends a powerful message to the Lukácsháza region. “We are aware of our importance as a local employer,” explains Christoph Döppes, Managing Director of the site in Lukácsháza.

“Our commitment here is long-term in nature and we are working together with the local authorities on further developing this site,” he adds.

Besides opening its new machine building facility, which received public funding support, and expanding its production capacities, SCHOTT also plans to create a number of new skilled jobs for machine builders, technicians and engineers, for instance.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCHOTT Committed to Further Investments in Brazilian Pharma Packaging Plant
Celebrating 80 years of ampoule manufacturing in Brazil.
Thursday, April 23, 2015
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!